文献速递泌尿生殖MR

多参数前列腺磁共振成像在主动监测中确认性活检前评估前列腺癌进展风险的作用

Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.
PubMed 文献 · Korean J Radiol · 2020-11-26

回顾性纳入2011至2019年170例初入主动监测的Gleason 6级前列腺癌患者,确认性活检前mpMRI见可疑病灶(PI-RADS≥3)者活检再分类率66%,高于非可疑mpMRI者的26.2%和未行mpMRI者的24.2%(p<0.001);可疑mpMRI与再分类风险(校正OR 4.72)及随访中进展至积极治疗风险(校正HR 2.62)相关。

要点

  • 确认性活检前mpMRI见PI-RADS≥3可疑病灶者再分类率66%,显著高于非可疑mpMRI者的26.2%和未行mpMRI者的24.2%。
  • 校正主要变量后,可疑mpMRI与确认性活检再分类风险相关,校正OR 4.72。
  • 可疑mpMRI亦与随访中进展至积极治疗风险相关,校正HR 2.62。

关键影像表现/征象

  • mpMRI可疑病灶定义为PI-RADS评分≥3。
  • mpMRI可疑者47例,mpMRI非可疑者61例,未行mpMRI者62例。

诊断标准与关键数值

  • 确认性活检再分类率:mpMRI可疑(PI-RADS≥3)者66%,mpMRI非可疑者26.2%,未行mpMRI者24.2%(p<0.001)。
  • 多因素分析中,可疑mpMRI表现(PI-RADS≥3)与确认性活检再分类风险相关,校正OR 4.72,校正变量包括年龄、前列腺特异抗原密度、阳性针数、既往活检次数和临床分期。
  • 可疑mpMRI表现与随访中进展至积极治疗风险相关,校正HR 2.62。

临床应用与阅片要点

  • 确认性活检前mpMRI显示PI-RADS≥3可疑病灶,提示活检再分类风险较高。
  • 确认性活检前mpMRI显示PI-RADS≥3可疑病灶,提示随访中进展至积极治疗风险较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the impact of multiparametric magnetic resonance imaging (mpMRI) before confirmatory prostate biopsy in patients under active surveillance (AS).

MATERIALS AND METHODS: This retrospective study included 170 patients with Gleason grade 6 prostate cancer initially enrolled in an AS program between 2011 and 2019. Prostate mpMRI was performed using a 1.5 tesla (T) magnetic resonance imaging system with a 16-channel phased-array body coil. The protocol included T1-weighted, T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging sequences. Uroradiology reports generated by a specialist were based on prostate imaging-reporting and data system (PI-RADS) version 2. Univariate and multivariate analyses were performed based on regression models.

RESULTS: The reclassification rate at confirmatory biopsy was higher in patients with suspicious lesions on mpMRI (PI-RADS score ≥ 3) (n = 47) than in patients with non-suspicious mpMRIs (n = 61) and who did not undergo mpMRIs (n = 62) (66%, 26.2%, and 24.2%, respectively; p < 0.001). On multivariate analysis, presence of a suspicious mpMRI finding (PI-RADS score ≥ 3) was associated (adjusted odds ratio: 4.72) with the risk of reclassification at confirmatory biopsy after adjusting for the main variables (age, prostate-specific antigen density, number of positive cores, number of previous biopsies, and clinical stage). Presence of a suspicious mpMRI finding (adjusted hazard ratio: 2.62) was also associated with the risk of progression to active treatment during the follow-up.

CONCLUSION: Inclusion of mpMRI before the confirmatory biopsy is useful to stratify the risk of reclassification during the biopsy as well as to evaluate the risk of progression to active treatment during follow-up.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Salguero J, Gómez-Gómez E, Valero-Rosa J, et al. Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance. Korean J Radiol. 2020. PMID: 33289358. doi:10.3348/kjr.2020.0852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。